You are here

Product Pipeline

OUR MEDICINES IN DEVELOPMENT

Our priority is researching and developing medicines and vaccines that will benefit patients around the world. We are committed to addressing unmet needs across a number of important therapeutic areas including, Oncology, Inflammation & Immunology, Vaccines, Internal Medicine and Rare Disease, with the goal of delivering innovative products to patients. 

Key Innovative Programs

Pipeline date and pdf

Pipeline Snapshot as of January 28, 2020

  • Discovery Projects
  • Phase 1
    26
  • Phase 2
    37
  • Phase 3
    23
  • Registration
    9
  • Total95
 
Compound Name
Indication
Phase
Submission Typesort descending
Compound Type
Vyndaqel (tafamidis meglumine)
Therapeutic Area:
Rare Diseases
Phase:Registration
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
Transthyretin (TTR) Dissociation Inhibitor
Go to clinical trial
Transthyretin familial amyloid polyneuropathy (U.S.) (FAST TRACK, ORPHAN - U.S.) Registration New Molecular Entity Small Molecule
PF-06835375
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
WRDM
Mechanism of Action:
chemokine inhibitor
Go to clinical trial
Lupus (Biologic) Phase 1 New Molecular Entity Biologic
Daurismo (glasdegib)
Therapeutic Area:
Oncology
Phase:Registration
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
SMO (smoothened) antagonist
Go to clinical trial
Combo w/ low-dose cytarabine (LDAC) for Acute Myeloid Leukemia (E.U.) Registration New Molecular Entity Small Molecule
Dekavil
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 2
Compound Type:Biologic
Business Segment:
WRDM
Mechanism of Action:
IL-10
Go to clinical trial
Rheumatoid Arthritis (Biologic) Phase 2 New Molecular Entity Biologic
tanezumab
Therapeutic Area:
Internal Medicine
Phase:Phase 3
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Nerve Growth Factor Inhibitor
Go to clinical trial
OA Signs and Symptoms (FAST TRACK), Chronic Low Back Pain (FAST TRACK), Cancer Pain (Biologic) Phase 3 New Molecular Entity Biologic
somatrogon (PF-06836922)
Therapeutic Area:
Rare Diseases
Phase:Phase 3
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Human Growth Hormone Agonist
Go to clinical trial
Pediatric Growth Hormone Deficiency (Biologic) (ORPHAN - U.S., E.U.) Phase 3 New Molecular Entity Biologic
rivipansel (GMI-1070)
Therapeutic Area:
Rare Diseases
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
Pan-Selectin Antagonist
Go to clinical trial
Acute vaso-occlusive crises associated with sickle cell disease in patients aged 6 years and above (FAST TRACK, ORPHAN - U.S., E.U.) Phase 3 New Molecular Entity Small Molecule
PF-07265803
Therapeutic Area:
Rare Diseases
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
p38 Mitogen-Activated Protein Kinase
Go to clinical trial
Dilated Cardiomyopathy due to Lamin A/C Gene Mutation Phase 3 New Molecular Entity Small Molecule
PF-06801591 + Bacillus Calmette-Guerin (BCG)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Biologic
Business Segment:
WRDM
Mechanism of Action:
Anti-PD-1
Go to clinical trial
Non-Muscle-Invasive Bladder cancer (Biologic)
Project advanced
Phase 3 New Molecular Entity Biologic
PF-06823859
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 2
Compound Type:Biologic
Business Segment:
WRDM
Mechanism of Action:
interferon, beta 1, fibroblast (IFNB1) Blocker
Go to clinical trial
Inflammatory Disorders (Biologic) Phase 2 New Molecular Entity Biologic
PF-06482077
Therapeutic Area:
Vaccines
Phase:Phase 3
Compound Type:Vaccine
Business Segment:
Biopharma
Mechanism of Action:
Prophylactic Vaccine
Go to clinical trial
Invasive and non-invasive Pneumococcal infections (adult) (BREAKTHROUGH) Phase 3 New Molecular Entity Vaccine
PF-06425090
Therapeutic Area:
Vaccines
Phase:Phase 3
Compound Type:Vaccine
Business Segment:
Biopharma
Mechanism of Action:
Prophylactic Vaccine
Go to clinical trial
Primary clostridioides difficile infection (FAST TRACK) Phase 3 New Molecular Entity Vaccine
fidanacogene elaparvovec (PF-06838435)
Therapeutic Area:
Rare Diseases
Phase:Phase 3
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Gene Therapy, coagulation factor IX (F9)
Go to clinical trial
Hemophilia (Biologic) (BREAKTHROUGH, ORPHAN - U.S., E.U., PRIME - E.U.) Phase 3 New Molecular Entity Biologic
aztreonam-avibactam (PF-06947387)
Therapeutic Area:
Hospital (Anti-Infectives)
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
Beta Lactam/Beta Lactamase Inhibitor
Go to clinical trial
Treatment of infections caused by Gram-negative bacteria for which there are limited or no treatment options Phase 3 New Molecular Entity Small Molecule
PF-06650833
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
IRAK4
Go to clinical trial
Rheumatoid Arthritis Phase 2 New Molecular Entity Small Molecule
PF-07285557
Therapeutic Area:
Internal Medicine
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
Angiopoietin Like 3(ANGPTL3)
Go to clinical trial
Cardiovascular Risk Reduction, Severe Hypertriglyceridemia
Project advanced
Phase 2 New Molecular Entity Small Molecule
PF-07055480 (SB-525)
Therapeutic Area:
Rare Diseases
Phase:Phase 2
Compound Type:Biologic
Business Segment:
WRDM
Mechanism of Action:
AAV-FVIII GTx
Go to clinical trial
Hemophilia (Biologic) (RMAT, FAST TRACK, ORPHAN - U.S.; ORPHAN - E.U.) Phase 2 New Molecular Entity Biologic
PF-07055341
Therapeutic Area:
Internal Medicine
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
ACCi and DGAT2 Combination
Go to clinical trial
Combo of PF-05221304 and PF-06865571 for Non-Alcoholic Steatohepatitis (NASH) Phase 2 New Molecular Entity Small Molecule